▶주메뉴 바로가기

▶본문 바로가기

THE INVESTOR
January 16, 2018

Bio & Medicine

Metabolic cancer drug developer Haim Bio raises W3b funding

  • PUBLISHED :December 05, 2017 - 15:29
  • UPDATED :December 05, 2017 - 15:29
  • 폰트작게
  • 폰트크게
  • facebook
  • twitter
  • sms
  • print
[THE INVESTOR] Korean biopharmaceutical firm Haim Bio, which develops a metabolic cancer drug, said on Dec. 5 it has attracted 3 billion won (US$2.75 million) from angel investors.

The company said it plans to complete the phase 1 clinical trials of its next-generation oncology treatment candidate that starves out cancer cells by the first half of 2019. 


7STOCK CEO Song Young-bong (left) and Haim Bio CEO Kim Hong-ryeol.


Haim Bio hopes to commercialize the drug NYH817100 before 2020 by conducting the phase 2 clinical studies for patients with brain, gastric and pancreatic cancer in August 2019.

The investments came as the biotech startup forged a partnership with Korean consulting firm 7STOCK in August to raise funds for the new drug development.

“With the 3 billion won investment, Haim Bio’s oncology drug development will further gather momentum,” 7STOCK CEO Song Young-bong.

This year, Haim Bio acquired the technology involving metabolic targeted therapy of cancer from Korea’s National Cancer Center, following a license-in deal for oncology treatment technology for lung, gastric and brain cancer, co-developed by the center and Yonsei Severance Hospital.

By Park Han-na (hnpark@heraldcorp.com)
  • facebook
  • twitter
  • sms
  • print

EDITOR'S PICKS